Chart Analysis
HYD Daily Timeframe Chart as of 20 May 2026
Hydrix (ASX: HYD) Converts A$5.1M Debt to Equity and Raises A$3.89M at $0.005 — Balance Sheet Reset Anchored by A$1.2M NIOA Counter-Drone Contract
A medtech company pivoting into defence has restructured its balance sheet through a combination of a A$8.18 million entitlement offer (A$3.89 million raised institutionally at $0.005 per share) and A$5.113 million in director and noteholder debt-to-equity conversion. The 6:1 entitlement ratio with free 1:1 attaching options at $0.01 exercise will result in approximately 600% dilution before accounting for debt conversion shares. The catalyst underpinning the raise is a binding A$1.2 million contract with NIOA Group for counter-UAS kinetic effector payload development, announced 14 May 2026. The stock moved +38.5% to $0.018 on 20 May 2026 — though it traded as high as $0.035 (+169%) before a 49% intraday reversal, the most severe session fade in this article series.
The Balance Sheet Restructure — Debt Paydown and Dilution
| Component | Value |
|---|---|
| Institutional raise (completed) | A$3.89 million at $0.005 |
| Retail component (opens 25 May) | Up to ~A$4.3 million at $0.005 |
| Debt converted to equity | A$5.113 million (directors + convertible noteholders) |
| Entitlement ratio | 6 new shares for every 1 held |
| Free attaching options | 1:1 at $0.01 exercise, expiry 30 June 2029 |
| Use of proceeds (if max raised) | A$4.79M debt paydown + A$0.78M costs + A$2.61M working capital |
The proceeds allocation tells the story: 59% of the maximum raise goes straight to retiring debt and operating liabilities, with only 32% (A$2.61 million) available for working capital and defence growth. The A$5.1 million debt conversion suggests the debt was unlikely to be repaid in cash — the balance sheet was stressed before this restructure. The $0.005 issue price sits approximately 72% below the pre-announcement close of $0.013.
The NIOA Contract — What Hydrix Is Actually Building
The binding A$1.2 million contract with NIOA Group involves developing kinetic effector payloads for counter-drone applications. NIOA operates across four countries with distribution spanning 75 US State Department-approved countries. Hydrix's role is providing mission-critical embedded electronics, software engineering, and systems integration — capabilities developed over many years in the medtech sector, including safety-critical control systems for total artificial hearts and LVADs.
The company cites the global C-UAS market at approximately US$6.6 billion (2025), forecast to reach US$20.3 billion by 2030. Australia's 2026 National Defence Strategy allocates up to A$7 billion to counter-drone capability within the A$425 billion Integrated Investment Program. However, the NIOA contract is a single A$1.2 million engagement — the broader defence pipeline is aspirational and has not been quantified.
Risks & Considerations
The 49% intraday reversal from $0.035 to $0.018 is the most severe session fade in this article series — the stock gave back nearly two-thirds of its intraday gains. This pattern, combined with a 6:1 entitlement ratio at a 72% discount and A$5.1 million in forced debt-to-equity conversion, indicates a company in financial distress executing a rescue recapitalisation rather than a growth-phase capital raise.
The defence pivot rests on a single A$1.2 million contract. While the medtech-to-defence engineering crossover is conceptually valid (safety-critical embedded systems for cardiac devices share design principles with defence electronics), Hydrix has not demonstrated an ability to scale defence revenue beyond this initial engagement. Revenue, profitability, and cash position were not disclosed.
The retail component (~A$4.3 million) opens 25 May with a shortfall bookbuild on 10 June. There is no certainty it will be fully subscribed. If the retail raise falls short, the proportion of proceeds available for working capital (already only 32% of maximum) would shrink further.
Key Dates & Timeline
| Date | Event |
|---|---|
| 14 May 2026 | Binding A$1.2M C-UAS contract with NIOA Group |
| 20 May 2026 | Institutional raise completed; debt conversion announced; share price moved +38.5% |
| 25 May 2026 | Retail component opens |
| 10 June 2026 | Retail shortfall bookbuild |
| 30 June 2029 | Attaching option expiry |
Price Data
- Previous Close: $0.013
- Close Price (20 May 2026): $0.018
- Change (20 May 2026): +38.5%
- 52-Week Range: $0.010 – $0.035
Notable Price Levels
-
$0.035 — 52-week high and intraday high, set then immediately rejected on announcement day. The 49% reversal to close ($0.035→$0.018) is the sharpest intraday fade in this article series. Sellers overwhelmed buyers at this level, likely using the spike as a liquidity event. A confirmed ceiling.
-
$0.018 — announcement-day close, in the lower third of the session's range despite the +38.5% gain. At this level the stock trades at 3.6x the $0.005 entitlement price — meaning new shares from the raise are immediately in-the-money by 260%, which may create selling pressure as they settle.
-
$0.013 — undisturbed close and the pre-announcement equilibrium. The $0.005 entitlement price represents a 62% discount to this level. A retracement here would fully unwind the announcement premium.
-
$0.010 — 52-week low and the approximate zone where the $0.005 issue price plus $0.01 option exercise converge ($0.015 combined cost). Below $0.010, the balance sheet restructure thesis — that dilution at $0.005 was worthwhile for the defence pivot — would be seriously tested.
Summary
Hydrix completed the institutional component of a A$8.18 million entitlement offer at $0.005 per share (6:1 ratio with free 1:1 options at $0.01) and secured A$5.113 million in debt-to-equity conversion — a balance sheet restructure that retires A$4.79 million in debt but delivers only A$2.61 million in working capital for the defence pivot. The raise follows a binding A$1.2 million NIOA Group contract for counter-UAS kinetic effector payloads. The stock moved +38.5% to $0.018 on 20 May 2026 after spiking +169% to $0.035 intraday and reversing 49% — the sharpest session fade in this article series. The entitlement price of $0.005 is approximately 72% below the pre-announcement close, and the ~600% dilution from the 6:1 ratio (before debt conversion) reflects a distressed recapitalisation. The retail component (~A$4.3 million) opens 25 May 2026.
This article is for informational purposes only and does not constitute financial advice. Market Flow does not recommend buying or selling any securities. Past performance is not indicative of future results. Readers should conduct their own independent research and consult a licensed financial adviser before making any investment decisions. This content is published in accordance with ASX Market Rules and is not a financial product recommendation.
